Calcitriol restores renovascular function in estrogen-deficient rats through downregulation of cyclooxygenase-2 and the thromboxane-prostanoid receptor

Kidney International

Volumn 84, Issue 1, 2013, Pages 54-63

  Dong, Jinghui ^a   Wong, Siu Ling ^a   Lau, Chi Wai ^a   Liu, Jian ^a   Wang, Yi Xiang ^b   He, Zhen Dan ^c   Ng, Chi Fai ^b   Chen, Zhen Yu ^b   Yao, Xiaoqiang ^a   Xu, Aimin ^d   Ni, Xiaochen ^e   Wang, Hongyan ^e   Huang, Yu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Shenzhen University   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; CALCITRIOL; CELECOXIB; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE; TERUTROBAN; THROMBOXANE RECEPTOR; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ESTROGEN DEFICIENCY; EX VIVO STUDY; FEMALE; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; RENAL PROTECTION; RENOVASCULAR DISEASE; VITAMIN BLOOD LEVEL;

EID: 84879692662     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.12     Document Type: Article

References (49)

1. Rosano GM, Maffei S, Andreassi MG et al. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. J Cardiovasc Med (Hagerstown) 2009; 10: 85-92.
2. Kaunitz AM, McClung MR, Feldman RG et al. Postmenopausal osteoporosis: fracture risk and prevention. J Fam Pract 2009; 58: S1-S6.
3. Pouilles JM, Tremollieres FA, Ribot C. Osteoporosis in otherwise healthy perimenopausal and early postmenopausal women: physical and biochemical characteristics. Osteoporos Int 2006; 17: 193-200.
4. Mendelsohn ME. Mechanisms of estrogen action in the cardiovascular system. J Steroid Biochem Mol Biol 2000; 74: 337-343.
5. Popat VB, Calis KA, Vanderhoof VH et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 2009; 94: 2277-2283.
6. Holick MF. Evolution and function of vitamin D. Recent Results Cancer Res 2003; 164: 3-28.
7. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147: 5542-5548.
8. Pilz S, Tomaschitz A, Ritz E et al. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 2009; 6: 621-630.
9. Moreno J, Krishnan AV, Feldman D. Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer. J Steroid Biochem Mol Biol 2005; 97: 31-36.
10. Moreno J, Krishnan AV, Peehl DM et al. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 2006; 26: 2525-2530.
11. Feletou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 2011; 164: 894-912.
12. Wong SL, Wong WT, Tian XY et al. Prostaglandins in action indispensable roles of cyclooxygenase-1 and -2 in endothelium-dependent contractions. Adv Pharmacol 2010; 60: 61-83.
13. Remuzzi G, FitzGerald GA, Patrono C. Thromboxane synthesis and action within the kidney. Kidney Int 1992; 41: 1483-1493.
14. Sebekova K, Eifert T, Klassen A et al. Renal effects of S18886 (terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes. Diabetes 2007; 56: 968-974.
15. Belhassen L, Pelle G, Dubois-Rande JL et al. Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41: 1198-1204.
16. Versari D, Daghini E, Virdis A et al. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 2009; 157: 527-536.
17. Chenevard R, Hurlimann D, Bechir M et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107: 405-409.
18. Widlansky ME, Price DT, Gokce N et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003; 42: 310-315.
19. Marnett LJ. The coxib experience: a look in the rearview mirror. Annu Rev Pharmacol Toxicol 2009; 49: 265-290.
20. Griffoni C, Spisni E, Strillacci A et al. Selective inhibition of prostacyclin synthase activity by rofecoxib. J Cell Mol Med 2007; 11: 327-338.
21. Ishizuka T, Higashino H. TP receptor as a therapeutic target in atherosclerosis and related cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2006; 1: 241-247.
22. Higashi Y, Oshima T, Ozono R et al. Aging and severity of hypertension attenuate endothelium-dependent renal vascular relaxation in humans. Hypertension 1997; 30: 252-258.
23. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828.
24. Alborzi P, Patel NA, Peterson C et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255.
25. Francois H, Jacquet A, Beaudreuil S et al. Emerging strategies to preserve renal function. J Nephrol 2011; 24: 133-141.
26. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (vital study): a randomised controlled trial. Lancet 2010; 376: 1543-1551.
27. Koleganova N, Piecha G, Ritz E et al. Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant 2009; 24: 778-787.
28. Doorenbos CR, van den Born J, Navis G et al. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol 2009; 5: 691-700.
29. Halligan SC, Murtagh B, Lennon RJ et al. Effect of long-term hormone replacement therapy on coronary endothelial function in postmenopausal women. Mayo Clin Proc 2004; 79: 1514-1520.
30. Yung LM, Wong WT, Tian XY et al. Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats. PLoS One 2011; 6: e17437.
31. Wong WT, Wong SL, Tian XY et al. Endothelial dysfunction: the common consequence in diabetes and hypertension. J Cardiovasc Pharmacol 2010; 55: 300-307.
32. Wong WT, Tian XY, Chen Y et al. Bone morphogenic protein-4 impairs endothelial function through oxidative stress-dependent cyclooxygenase-2 upregulation: implications on hypertension. Circ Res 2010; 107: 984-991.
33. Tian XY, Wong WT, Leung FP et al. Oxidative stress-dependent cyclooxygenase-2-derived prostaglandin F2a impairs endothelial function in renovascular hypertensive rats. Antioxid Redox Signal 2012; 16: 363-373.
34. Wong SL, Lau CW, Wong WT et al. Pivotal role of protein kinase Cd in angiotensin II-induced endothelial cyclooxygenase-2 expression: a link to vascular inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 1169-1176.
35. Liu CQ, Leung FP, Wong SL et al. Thromboxane prostanoid receptor activation impairs endothelial nitric oxide-dependent vasorelaxations: the role of Rho kinase. Biochem Pharmacol 2009; 78: 374-381.
36. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26: 662-687.
37. Aparna R, Subhashini J, Roy KR et al. Selective inhibition of cyclooxygenase-2 (COX-2) by 1a,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog. J Cell Biochem 2008; 104: 1832-1842.
38. Ishizuka S, Kurihara N, Miura D et al. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1a,25-dihydroxyvitamin D3 from pagetic bone marrow cells. J Steroid Biochem Mol Biol 2004; 89-90: 331-334.
39. Cayatte AJ, Du Y, Oliver-Krasinski J et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apoEdeficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-1728.
40. Michel F, Simonet S, Vayssettes-Courchay C et al. Altered TP receptor function in isolated, perfused kidneys of nondiabetic and diabetic ApoE-deficient mice. Am J Physiol Renal Physiol 2008; 294: F120-F129.
41. Lesault PF, Boyer L, Pelle G et al. Daily administration of the TP receptor antagonist terutroban improved endothelial function in highcardiovascular- risk patients with atherosclerosis. Br J Clin Pharmacol 2011; 71: 844-851.
42. Osende JI, Shimbo D, Fuster V et al. Antithrombotic effects of S18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost 2004; 2: 492-498.
43. Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16810-16815.
44. Dong J, Wong SL, Lau CW et al. Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress. Eur Heart J 2012; 33: 2980-2990.
45. Freundlich M, Quiroz Y, Zhang Z et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74: 1394-1402.
46. Zhang Z, Zhang Y, Ning G et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 105: 15896-15901.
47. Haffner D, Hocher B, Muller D et al. Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 2005; 23: 1067-1075.
48. Wong SL, Leung FP, Lau CW et al. Cyclooxygenase-2-derived prostaglandin F2a mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res 2009; 104: 228-235.
49. Yuen CY, Wong WT, Tian XY et al. Telmisartan inhibits vasoconstriction via PPARgamma-dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc Res 2011; 90: 122-129.